

# UbiQ

enabling ubiquitin-based drug discovery

[www.ubiqbio.com](http://www.ubiqbio.com)

## K119 Ub- $\gamma$ H2AX(115-143)-Ser140(PO4)-FP

UbiQ code : UbiQ-039

Batch # : B09082012-001

Protocol# : P09082012-001

### Product Information

Amount : 0.08 mg lyophilized powder

Purity :  $\geq$ 95% by RP-HPLC



Mol. Weight : 11.984 kDa by MS (cal 11.987 Da)

Storage :  $-20^{\circ}\text{C}$ ; buffered solution at  $-80^{\circ}\text{C}$ . Please avoid multiple freeze/thaw cycles.

**Background.** Class II fluorescence polarization HTS reagent<sup>1-4</sup> based on the peptide sequence 115 – 143 of the histone protein  $\gamma$ H2A-X, which is monoubiquitinated on Lys119 and phosphorylated on Ser140. The peptide is modified on the N-terminus with a 5-carboxytetramethylrhodamine, a phosphate group on Ser140 and conjugated at Lys119 to Ub via a native isopeptide bond.

**Important: sample preparation.** Dissolve the powder in as little DMSO as possible (e.g. 12 mg/mL = 1000  $\mu\text{M}$ ) and add this DMSO stock to the required buffer (please note the order of addition).

### Structure (5-TAMRA)-VLLPK<sup>119</sup>(Ub)KTSATVGPKAPS<sup>140</sup>(PO<sub>4</sub>)QEY



**LC-MS analysis.** Mobile phase A = 1% CH<sub>3</sub>CN, 0.1% formic acid in water (milliQ) and B = 1% water (milliQ) and 0.1% formic acid in CH<sub>3</sub>CN. Phenomenex Kinetex C18, (2.1 $\times$ 50 mm, 2.6  $\mu\text{m}$ ); flow rate = 0.5 mL/min, runtime = 6 min, column T = 40°C. Gradient: 5%  $\Rightarrow$  95% over 3.5 min.

### Literature.

- (1) Tirat, A. et al. *Anal. Biochem.* **2005**, 343, 244-255. (2) Huang et al. *Methods in Molecular Biology* **2009**, 565, 127.  
(3) Levine et al. *Anal. Biochem.* **1997**, 247, 83. (4) Geurink and El Oualid et al. *ChemBioChem*, **2012**, 13, 293.

**For Laboratory Research Use Only, Not For Use in Humans**

09 Augustus 2012

Amsterdam, The Netherlands